Telix Pharmaceuticals (TLX) files Form 6-K on first ProstACT Global patient

Rhea-AI Filing Summary

Telix Pharmaceuticals Limited submitted a Form 6-K to update U.S. investors on a clinical development milestone first disclosed in Australia. On December 8, 2025, the company filed an announcement with the Australian Securities Exchange titled “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” and this announcement is attached to the Form 6-K as Exhibit 99.1. The filing itself mainly serves as a cross-border notice and does not include additional financial results or transaction details beyond referencing the attached announcement.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2025

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

1

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On December 8, 2025 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” which is attached to this Form 6-K as Exhibit 99.1.

99.1 Press release – December 8, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: December 8, 2025	By:	/s/ Genevieve Ryan
		Name: Genevieve Ryan
		Title: Company Secretary

FAQ

What does Telix Pharmaceuticals Limited (TLX) report in this Form 6-K?

The Form 6-K reports that on December 8, 2025 Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” which is attached as Exhibit 99.1.

What is the title of the Telix Pharmaceuticals (TLX) announcement referenced in the Form 6-K?

The referenced announcement is titled “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” indicating that the first patient has been dosed in that clinical study expansion.

When was the Telix Pharmaceuticals (TLX) ASX announcement filed that is attached to this Form 6-K?

The announcement attached to the Form 6-K as Exhibit 99.1 was filed with the Australian Securities Exchange on December 8, 2025 in Melbourne, Australia.

Does this Telix Pharmaceuticals (TLX) Form 6-K include detailed financial results?

No. This Form 6-K serves primarily to furnish the attached Australian Securities Exchange announcement about the ProstACT Global randomized treatment expansion and does not present separate financial results.

Who signed the Telix Pharmaceuticals Limited (TLX) Form 6-K?

The Form 6-K was signed on behalf of Telix Pharmaceuticals Limited by Genevieve Ryan, who is identified as the company’s Company Secretary, dated December 8, 2025.

What is the purpose of Telix Pharmaceuticals (TLX) using Form 6-K here?

Telix Pharmaceuticals Limited is using Form 6-K to provide U.S. investors with an English-language copy of its Australian Securities Exchange announcement about the first patient dosed in the ProstACT Global randomized treatment expansion.